Latest Dental Products News

SDI Limited’s acquisition by Beijing Guoci subsidiary is now effective following New South Wales Supreme Court approval, with the ASX suspension commencing and cash payout scheduled for early July.

The Supreme Court of New South Wales has approved the scheme of arrangement for SDI Limited’s acquisition by Beijing Guoci’s subsidiary, paving the way for a cash payout and ASX suspension.

Osteopore Limited reported a 30% year-on-year revenue increase in Q4 CY25, overcoming a slowdown in South Korea, and secured a strategic five-year partnership with DKSH Malaysia to expand its dental product reach.

SDI Limited reported stable FY25 revenue with improved margins and advancing Montrose project, while regional sales showed mixed results.

Osteopore Limited has partnered with DKSH Malaysia in a five-year agreement to distribute its innovative dental products, aiming to capture significant growth in Malaysia’s guided bone regeneration sector.

Orthocell Ltd reported a record $9.23 million revenue for FY25, driven by strong sales of its nerve repair and dental products, alongside securing US FDA clearance for its flagship nerve repair device Remplir. The company is poised for accelerated growth as it expands its global commercial footprint.

SDI Limited’s FY25 results reveal steady revenue with improved margins driven by operational efficiencies and strong European and Brazilian sales. The company is progressing its Montrose facility project and advancing ESG initiatives.

Orthocell Limited has reported a record FY2025 revenue of A$9.19 million, driven by strong sales of its nerve repair product Remplir™ in Australia and a promising US market launch following FDA clearance.